Dienvidāfrikas Republika - angļu - South African Health Products Regulatory Authority (SAHPRA)

pharmacare limited û woodmead - tablet - see ingredients - each tablet contains ranitidine hydrochloride 336,0 mg equivalent to 300 mg ranitidine

Dienvidāfrikas Republika - angļu - South African Health Products Regulatory Authority (SAHPRA)

glaxosmithkline south africa (pty) limited - tablet - each tablet contains ranitidine hydrochloride 168 mg equivalent to 150 mg ranitidine

Dienvidāfrikas Republika - angļu - South African Health Products Regulatory Authority (SAHPRA)

glaxosmithkline south africa (pty) limited - tablet - each tablet contains ranitidine hydrochloride 336 mg equivalent to 300 mg ranitidine

Dienvidāfrikas Republika - angļu - South African Health Products Regulatory Authority (SAHPRA)

glaxosmithkline south africa (pty) limited - tablet - each tablets contains ranitidine hydrochloride equivalent to 300 mg ranitidine

Dienvidāfrikas Republika - angļu - South African Health Products Regulatory Authority (SAHPRA)

glaxosmithkline south africa (pty) limited - tablet - each tablet contains ranitidine hydrochloride equivalent to ranitidine 150 mg

Dienvidāfrikas Republika - angļu - South African Health Products Regulatory Authority (SAHPRA)

glaxosmithkline south africa (pty) limited - tablet - each tablet contains ranitidine hydrochloride 84 mg

Dienvidāfrikas Republika - angļu - South African Health Products Regulatory Authority (SAHPRA)

glaxosmithkline south africa (pty) limited - tablet - each tablet contains ranitidine hydrochloride equivalent to ranitidine 75,0 mg

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - ranitidine hydrochloride, quantity: 336 mg (equivalent: ranitidine, qty 300 mg) - tablet, effervescent - excipient ingredients: povidone; sodium bicarbonate; aspartame; sodium benzoate; monosodium dihydrogen citrate; flavour - 1. short-term treatment of provenduodenal ulcer and gastric ulcer, including intravenous use for prophylaxis against recurrent haemorrhage. 2. maintenance treatment to reduce the risk of relapse in duodenal ucler. 3. maintenance treatment for periods up to one year to reduce the risk of relapse in patients with documented healing of benign gastric ulcer. 4. treatment of gastrinoma (zollinger-ellison syndrome). 5. short-term symptomatic treatment of reflux oesophagitis unresponsive to conservative anti-reflux measures and simple drug therapies such as antacids. 6. maintenance treatment to reduce the risk of relapse of reflux oesophagitis. 7. treatment of scleroderma oesophagitis. the intravenous injection is indicated where oral treatment is inappropriate.

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - ranitidine hydrochloride, quantity: 336 mg (equivalent: ranitidine, qty 300 mg) - tablet, effervescent - excipient ingredients: aspartame; sodium bicarbonate; monosodium dihydrogen citrate; povidone; sodium benzoate; flavour - 1. short-term treatment of provenduodenal ulcer and gastric ulcer, including intravenous use for prophylaxis against recurrent haemorrhage. 2. maintenance treatment to reduce the risk of relapse in duodenal ucler. 3. maintenance treatment for periods up to one year to reduce the risk of relapse in patients with documented healing of benign gastric ulcer. 4. treatment of gastrinoma (zollinger-ellison syndrome). 5. short-term symptomatic treatment of reflux oesophagitis unresponsive to conservative anti-reflux measures and simple drug therapies such as antacids. 6. maintenance treatment to reduce the risk of relapse of reflux oesophagitis. 7. treatment of scleroderma oesophagitis. the intravenous injection is indicated where oral treatment is inappropriate.

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - ranitidine hydrochloride, quantity: 168 mg (equivalent: ranitidine, qty 150 mg) - tablet, effervescent - excipient ingredients: sodium bicarbonate; sodium benzoate; aspartame; monosodium dihydrogen citrate; povidone; flavour - short term treatment of proven duodenal and gastric ulcer. maintenance treatment to reduce the risk of relapse in duodenal ulcer. maintenance treatment for periods up to one year to reduce the risk of relapse in patients with documented healing of benign gastric ulcer. treatment of gastrinoma (zollinger-ellison syndrome). short-term symptomatic treatment of reflux oesophagitis unresponsive to conservative anti-reflux measures and simple drug therapies such as antacids. treatment of scleroderma oesophagitis. indications as at 2 november 1993: 1. short-term treatment of proven duodenal ulcer and gastric ulcer, including intravenous use for prophylaxis against recurrent haemorrhage. 2. maintenance treatment to reduce the risk of relapse in duodenal ulcer. 3. maintenance treatment for periods up to one year to reduce the risk of relapse in patients with documented healing of benign gastric ulcer. 4. treatment of gastrinoma (zollinger-ellison syndrome). 5. short-term symptomatic treatment of reflux oesopha